Human TL1A-DR3 inhibition Kit (TR-FRET)

• Comprehensive validation - Validated with various antibody drugs.
• Simple and fast operation - No complicated washing steps, significantly reducing time.
• High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
• Accurate and reliable results - High sensitivity with minimal matrix effects.
• High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
• Fast completion - Results in just 1 hour.

The Human TL1A-DR3 inhibition Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human TL1A binding to human DR3 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of TL1A to bind to human DR3.

1. Store the unopened kit at 2-8°C upon receipt.

2. Locate the expiration date on the outer packaging and do not use reagents beyond their expiration date.

3. The opened kit should be stored according to the storage conditions listed in the Components Table. The shelf life of the opened kit is 30 days from the date of opening.

This Human TL1A-DR3 inhibition kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human TL1A and Europium-chelate labeled streptavidin as the donor and FA labeled human DR3 protein as the acceptor.

- In the absence of inhibitors for human TL1A binding to human DR3, the donor and acceptor are in close proximity due to the binding of human TL1A and FA-labeled human DR3. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.

- In the presence of inhibitors that block the binding of human TL1A to human DR3, the donor-acceptor interaction is disrupted, preventing FRET from occurring.